Abstract
Chlorthalidone is commonly used for blood pressure control in hypertensive patients. However, it increases sympathetic nervous system activity and insulin resistance. Both conditions are related with an elevated number of complications and worsen patients’ prognosis. Recently has been demonstrated that these adverse effects are avoided with spironolactone administration. Mechanisms to explain increasing sympathetic nervous activity and insulin resistance with chlorthalidone, but not with spironolactone are unclear and under investigation. It should be necessary to continue medical investigation on this field with long-term studies, a larger number of patients and associated comorbidities. The aim should be to establish whether the association of both drugs could be an effective and safety choice to be implemented extensively in clinical practice. That possibility could represent a new alternative for patients’ management.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chobanian AV, Bakris GL, Black HR et al (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206–1252
Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC guidelines for the management of hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart 34:2159–2219. doi:10.1093/eurheartj/eht151
Weber MA, Schiffrin EL, White WB et al (2014) Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 16:14–26. doi:10.1111/jch.12237
Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 34:709–717
Kumar N, Calhoun DA, Dudenbostel T (2013) Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control 6:139–151. doi:10.2147/IBPC.S33984
Weidmann P, Beretta-Piccoli C, Meier A et al (1983) Antihypertensive mechanism of diuretic treatment with chlorthalidone: complementary roles of sympathetic axis and sodium. Kidney Int 23:320–326
The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981–2997
Menon DV, Arbique D, Wang Z et al (2009) Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab 94:1361–1366. doi:10.1210/jc.2008-2660
Raheja P, Price A, Wang Z et al (2012) Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 60:319–325. doi:10.1161/HYPERTENSIONAHA.112.194787
Felder RB (2010) Mineralocorticoid receptors, inflammation and sympathetic drive in a rat model of systolic heart failure. Exp Physiol 95:19–25. doi:10.1113/expphysiol.2008.045948
Gomez-Sanchez EP (2010) The mammalian mineralocorticoid receptor: tying down a promiscuous receptor. Exp Physiol 95:13–18. doi:10.1113/expphysiol.2008.045914
Selvaraj J, Muthusamy T, Srinivasan C et al (2009) Impact of excess aldosterone on glucose homeostasis in adult male rat. Clin Chim Acta 407:51–57. doi:10.1016/j.cca.2009.06.030
Parati G, Esler M (2012) The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 33:1058–1066. doi:10.1093/eurheartj/ehs041
Reaven G (2012) Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb Vasc Biol 32:1754–1759. doi:10.1161/ATVBAHA.111.241885
Sica DA (2007) The risks and benefits of therapy with aldosterone receptor antagonist therapy. Curr Drug Saf 2:71–77
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work did not receive any funding.
Conflict of interest
Author Yaniel Castro-Torres declares that he has no conflict of interest. Author Anamary Fleites-Pérez declares that she has no conflict of interest. Author Raimundo Carmona-Puerta declares that he has no conflict of interest. Author Roger Gilbert Jiménez-Garrido declares that he has no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Castro-Torres, Y., Fleites-Pérez, A., Carmona-Puerta, R. et al. Negative effects of chlorthalidone on sympathetic nervous system and insulin resistance in hypertensive patients may be avoided with spironolactone: further studies are still needed. Ir J Med Sci 184, 727–729 (2015). https://doi.org/10.1007/s11845-015-1350-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-015-1350-1